Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
- Authors:
-
more »
- Humany and Helath Medical Centre, Hong Kong (China); Second Liver Cirrhosis Diagnosis and Treatment Center, Beijing (China)
- Pitie-Salpetriere Hospital Univ. Hospital, Paris (France)
- Second Liver Cirrhosis Diagnosis and Treatment Center, Beijing (China)
- Inst. of Infectious Disease, Beijing (China)
- Southern Medical Univ., Guangzhou (China). Dept. of Infectious Disease
- Humany and Helath Medical Centre, Hong Kong (China); Southern Medical Univ., Guangzhou (China). Dept. of Infectious Disease
- Humany and Helath Medical Centre, Hong Kong (China)
- Hong Kong Molecular Pathology Diagnostic Centre, Hong Kong (China)
- Emory Univ. School of Medicine, Atlanta, GA (United States). Center for AIDS Research
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics; North Carolina State Univ., Raleigh, NC (United States). Dept. of Mathematics
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics
- Publication Date:
- Research Org.:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE; National Institutes of Health (NIH)
- OSTI Identifier:
- 1360712
- Alternate Identifier(s):
- OSTI ID: 1364534
- Report Number(s):
- LA-UR-17-20260; LA-UR-15-28932
Journal ID: ISSN 2468-1253
- Grant/Contract Number:
- AC52-06NA25396; 5P30-AI-50409; R01-AI028433; R01-AI078881; R01-OD011095
- Resource Type:
- Accepted Manuscript
- Journal Name:
- The Lancet Gastroenterology & Hepatology
- Additional Journal Information:
- Journal Volume: 1; Journal Issue: 2; Journal ID: ISSN 2468-1253
- Publisher:
- Elsevier
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; Biological Science
Citation Formats
Lau, George, Benhamou, Yves, Chen, Guofeng, Li, Jin, Shao, Qing, Ji, Dong, Li, Fan, Li, Bing, Liu, Jialiang, Hou, Jinlin, Sun, Jian, Wang, Cheng, Chen, Jing, Wu, Vanessa, Wong, April, Wong, Chris L. P., Tsang, Stella T. Y., Wang, Yudong, Bassit, Leda, Tao, Sijia, Jiang, Yong, Hsiao, Hui-Mien, Ke, Ruian, Perelson, Alan S., and Schinazi, Raymond F. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. United States: N. p., 2016.
Web. doi:10.1016/S2468-1253(16)30015-2.
Lau, George, Benhamou, Yves, Chen, Guofeng, Li, Jin, Shao, Qing, Ji, Dong, Li, Fan, Li, Bing, Liu, Jialiang, Hou, Jinlin, Sun, Jian, Wang, Cheng, Chen, Jing, Wu, Vanessa, Wong, April, Wong, Chris L. P., Tsang, Stella T. Y., Wang, Yudong, Bassit, Leda, Tao, Sijia, Jiang, Yong, Hsiao, Hui-Mien, Ke, Ruian, Perelson, Alan S., & Schinazi, Raymond F. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. United States. https://doi.org/10.1016/S2468-1253(16)30015-2
Lau, George, Benhamou, Yves, Chen, Guofeng, Li, Jin, Shao, Qing, Ji, Dong, Li, Fan, Li, Bing, Liu, Jialiang, Hou, Jinlin, Sun, Jian, Wang, Cheng, Chen, Jing, Wu, Vanessa, Wong, April, Wong, Chris L. P., Tsang, Stella T. Y., Wang, Yudong, Bassit, Leda, Tao, Sijia, Jiang, Yong, Hsiao, Hui-Mien, Ke, Ruian, Perelson, Alan S., and Schinazi, Raymond F. Mon .
"Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study". United States. https://doi.org/10.1016/S2468-1253(16)30015-2. https://www.osti.gov/servlets/purl/1360712.
@article{osti_1360712,
title = {Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study},
author = {Lau, George and Benhamou, Yves and Chen, Guofeng and Li, Jin and Shao, Qing and Ji, Dong and Li, Fan and Li, Bing and Liu, Jialiang and Hou, Jinlin and Sun, Jian and Wang, Cheng and Chen, Jing and Wu, Vanessa and Wong, April and Wong, Chris L. P. and Tsang, Stella T. Y. and Wang, Yudong and Bassit, Leda and Tao, Sijia and Jiang, Yong and Hsiao, Hui-Mien and Ke, Ruian and Perelson, Alan S. and Schinazi, Raymond F.},
abstractNote = {},
doi = {10.1016/S2468-1253(16)30015-2},
journal = {The Lancet Gastroenterology & Hepatology},
number = 2,
volume = 1,
place = {United States},
year = {Mon Jul 25 00:00:00 EDT 2016},
month = {Mon Jul 25 00:00:00 EDT 2016}
}
Free Publicly Available Full Text
Publisher's Version of Record
Other availability
Search WorldCat to find libraries that may hold this journal
Cited by: 60 works
Citation information provided by
Web of Science
Web of Science
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
journal, August 2015
- Davis, Gary L.
- Hepatology, Vol. 62, Issue 3, p. 932-954
EASL Recommendations on Treatment of Hepatitis C 2015
journal, July 2015
- ,
- Journal of Hepatology, Vol. 63, Issue 1, p. 199-236
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
journal, April 2014
- Afdhal, Nezam; Reddy, K. Rajender; Nelson, David R.
- New England Journal of Medicine, Vol. 370, Issue 16
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
journal, May 2014
- Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender
- New England Journal of Medicine, Vol. 370, Issue 20
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
journal, January 2014
- Sulkowski, Mark S.; Gardiner, David F.; Rodriguez-Torres, Maribel
- New England Journal of Medicine, Vol. 370, Issue 3
Treating Hepatitis C in Lower-Income Countries
journal, May 2014
- Jayasekera, Channa R.; Barry, Michele; Roberts, Lewis R.
- New England Journal of Medicine, Vol. 370, Issue 20
Fake medicines are undermining global efforts to combat infectious disease, says US journal
journal, April 2015
- McCarthy, M.
- BMJ, Vol. 350, Issue apr21 21
Stopping Murder by Medicine: Introducing the Model Law on Medicine Crime
journal, June 2015
- Attaran, Amir
- The American Journal of Tropical Medicine and Hygiene, Vol. 92, Issue 6_Suppl
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals
journal, May 2014
- Hagan, Liesl M.; Sulkowski, Mark S.; Schinazi, Raymond F.
- Hepatology, Vol. 60, Issue 1
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
journal, January 2014
- Hill, A.; Khoo, S.; Fortunak, J.
- Clinical Infectious Diseases, Vol. 58, Issue 7
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
journal, March 2014
- Gane, Edward J.; Stedman, Catherine A.; Hyland, Robert H.
- Gastroenterology, Vol. 146, Issue 3
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
journal, March 2015
- Kohli, Anita; Osinusi, Anuoluwapo; Sims, Zayani
- The Lancet, Vol. 385, Issue 9973
Modelling hepatitis C therapy—predicting effects of treatment
journal, June 2015
- Perelson, Alan S.; Guedj, Jeremie
- Nature Reviews Gastroenterology & Hepatology, Vol. 12, Issue 8
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
journal, February 2012
- Guedj, Jeremie; Dahari, Harel; Shudo, Emi
- Hepatology, Vol. 55, Issue 4
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
journal, May 2011
- Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 53, Issue 6
Global distribution and prevalence of hepatitis C virus genotypes
journal, July 2014
- Messina, Jane P.; Humphreys, Isla; Flaxman, Abraham
- Hepatology, Vol. 61, Issue 1
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice
journal, July 2015
- Kai, Yugo; Hikita, Hayato; Tatsumi, Tomohide
- Journal of Gastroenterology, Vol. 50, Issue 11
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
journal, March 2015
- Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan
- The Lancet, Vol. 385, Issue 9973
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013
- Guedj, J.; Dahari, H.; Rong, L.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
journal, March 2013
- Rong, Libin; Guedj, Jeremie; Dahari, Harel
- PLoS Computational Biology, Vol. 9, Issue 3
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection: Hepatology, Vol. 00, No. X, 2014 Kumada et al.
journal, April 2014
- Kumada, Hiromitsu; Suzuki, Yoshiyuki; Ikeda, Kenji
- Hepatology, Vol. 59, Issue 6
O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks
journal, April 2015
- Poordad, F.; Lawitz, E.; Gutierrez, J. A.
- Journal of Hepatology, Vol. 62
P0875 : Predictors of sustained viral response to 4–6 week duration therapy with ledipasvir + sofosbuvir + GS-9451 +/− GS-9669 in early and advanced fibrosis (NIH/UMD synergy trial)
journal, April 2015
- Kattakuzhy, S.; Sidharthan, S.; Wilson, E.
- Journal of Hepatology, Vol. 62
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
journal, July 2012
- Lawitz, Eric J.; Gruener, Daniel; Hill, John M.
- Journal of Hepatology, Vol. 57, Issue 1
Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
journal, September 2014
- Svarovskaia, Evguenia S.; Dvory-Sobol, Hadas; Parkin, Neil
- Clinical Infectious Diseases, Vol. 59, Issue 12
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison
journal, May 2016
- Swallow, Elyse; Kelley, Caroline; Signorovitch, James
- Journal of Comparative Effectiveness Research, Vol. 5, Issue 3
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010
- Snoeck, E.; Chanu, P.; Lavielle, M.
- Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
journal, October 2016
- Reig, María; Mariño, Zoe; Perelló, Christie
- Journal of Hepatology, Vol. 65, Issue 4
Systematic review: Asian patients with chronic hepatitis C infection
journal, April 2013
- Nguyen, L. H.; Nguyen, M. H.
- Alimentary Pharmacology & Therapeutics, Vol. 37, Issue 10
Works referencing / citing this record:
Required concentration index quantifies effective drug combinations against hepatitis C virus infection
posted_content, January 2020
- Kakizoe, Yusuke; Koizumi, Yoshiki; Ikoma, Yukino
Management of acute HCV infection in the era of direct-acting antiviral therapy
journal, May 2018
- Martinello, Marianne; Hajarizadeh, Behzad; Grebely, Jason
- Nature Reviews Gastroenterology & Hepatology, Vol. 15, Issue 7
Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence
journal, July 2018
- Ke, Ruian; Li, Hui; Wang, Shuyi
- Proceedings of the National Academy of Sciences, Vol. 115, Issue 30
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam
journal, May 2020
- McCabe, Leanne; White, Ian R.; Chau, Nguyen Van Vinh
- Trials, Vol. 21, Issue 1
The preoperative management of Hepatitis C may improve the outcome after total knee arthroplasty
journal, June 2019
- Schwarzkopf, R.; Novikov, D.; Anoushiravani, A. A.
- The Bone & Joint Journal, Vol. 101-B, Issue 6
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations?
journal, February 2018
- Ferenci, P.
- Alimentary Pharmacology & Therapeutics, Vol. 47, Issue 6
Disentangling the lifespans of hepatitis C virus‐infected cells and intracellular vRNA replication‐complexes during direct‐acting anti‐viral therapy
journal, November 2019
- Cardozo, Erwing Fabian; Ji, Dong; Lau, George
- Journal of Viral Hepatitis, Vol. 27, Issue 3
Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis
journal, January 2019
- Jones, Christopher R.; Flower, Barnaby F.; Barber, Ella
- Wellcome Open Research, Vol. 4
Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients: SASAKI et al.
journal, October 2018
- Sasaki, Reina; Meyer, Keith; Moriyama, Mitsuhiko
- Journal of Medical Virology, Vol. 91, Issue 3
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
journal, December 2018
- Gambato, Martina; Canini, Laetitia; Lens, Sabela
- Liver International, Vol. 39, Issue 5
Utility of viral kinetics in HCV therapy – It is not over until it is over?
journal, February 2019
- Sandmann, Lisa; Manns, Michael P.; Maasoumy, Benjamin
- Liver International, Vol. 39, Issue 5
Hepatitis C virus infection
journal, March 2017
- Manns, Michael P.; Buti, Maria; Gane, Ed
- Nature Reviews Disease Primers, Vol. 3, Issue 1
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
journal, August 2018
- Raja, Rubesh; Baral, Subhasish; Dixit, Narendra M.
- Immunological Reviews, Vol. 285, Issue 1
Sustained virologic response with 6 weeks or less of direct‐acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system
journal, June 2019
- Joshi, Prajwol; Atherton, Amanda
- Journal of Gastroenterology and Hepatology, Vol. 34, Issue 12
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
journal, July 2018
- Venugopal, Vishnu; Padmanabhan, Pranesh; Raja, Rubesh
- PLOS Computational Biology, Vol. 14, Issue 7
Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs
journal, April 2019
- Raja, Rubesh; Pareek, Aditya; Newar, Kapil
- PLOS Pathogens, Vol. 15, Issue 4
Hepatitis C Virus Infection
book, November 2008
- Ahmed, Aijaz; Keeffe, Emmet B.
- Textbook of Gastroenterology
Hepatitis C virus infection
journal, February 2005
- Thomson, B. J.; Finch, R. G.
- Clinical Microbiology and Infection, Vol. 11, Issue 2
Required concentration index quantifies effective drug combinations against hepatitis C virus infection
journal, January 2021
- Kakizoe, Yusuke; Koizumi, Yoshiki; Ikoma, Yukino
- Theoretical Biology and Medical Modelling, Vol. 18, Issue 1
Required concentration index quantifies effective drug combinations against hepatitis C virus infection
posted_content, June 2020
- Kakizoe, Yusuke; Koizumi, Yoshiki; Ikoma, Yukino
Hepatitis C virus infection
journal, June 1994
- Craske, J.; Paver, W. K.; Neeleman, J.
- BMJ, Vol. 308, Issue 6945